Just a clarifying note: mutations and foreign proteins are not always responsible for the effectiveness of TILs in all cases. For instance, in a report from this year, patients with HPV (Human Papilloma Virus) positive cervical cancer were treated with TILs. It was expected that most of the TILs would be directed to HPV antigens or mutated protein (neo-antigens) because both would be maximally foreign to the immune system. However, it was determined that T cells against the wild-type protein CT83 (also known as KK-LC-1; which is a wild-type cancer associated antigen) dominated the response in at least one patient.